Stocks to Watch: KFin Technologies, Brigade Enterprises, RVNL, and More
Key stocks to watch include KFin Technologies, Brigade Enterprises, and KEC International, among others, as they make significant moves in their respective sectors. IT stocks are also expected to be in focus following recent H-1B visa rule changes.
Real Estate:Here are a few stocks to watch for tomorrow: Glenmark Pharma ahead of its board meet on interim dividend, Brigade Enterprises with a ₹1,200 crore Bengaluru project, and KEC International on bagging record T&D orders. IT stocks may stay in focus after H-1B jitters, while KFin Tech, Emkay Global, Birla Corp, RVNL, Alkem Labs, and Suraj Estate will also be on investors’ radar.
Private equity firm General Atlantic may sell a 10–15% stake in KFin Technologies through block deals at a 5–8% discount, sources told CNBC-TV18. From Q3FY24 to Q1FY26, General Atlantic sold a total of 26% in the company and currently holds a 22.9% stake.
Glenmark Pharmaceuticals, the pharma major, said its board will meet on September 26 to consider an interim dividend for FY26, with a record date of September 30.
Brigade Enterprises, a leading real estate developer, signed a joint development agreement for a ₹1,200 crore residential project in Banashankari, south Bengaluru, spanning 7.5 acres. The project aims to offer premium, high-quality living spaces.
KEC International, an infrastructure solutions provider, has bagged ₹3,243 crore worth of new T&D orders, including its largest-ever EPC order, spanning 400 kV transmission lines in the UAE and the supply of towers, hardware, and poles in the Americas.
IT stocks will likely be in focus again tomorrow after H-1B visa rule changes, wiping out nearly ₹1 lakh crore in market value, led by TCS and Infosys. Together, the two contributed over ₹51,000 crore to the ₹85,000 crore hit, while LTIMindtree, HCLTech, Wipro, Tech Mahindra, and others also saw sharp losses.
Emkay Global Financial Services, a leading investment bank, announced that industry veteran Kirti Doshi has acquired a 21% stake for ₹227.5 crore via Antique Securities. Doshi brings nearly five decades of capital market experience.
Birla Corporation, a major cement manufacturer, said its wholly-owned subsidiary, RCCPL, has been declared the preferred bidder for the Guda-Rampur limestone and manganese block in Telangana.
Rail Vikas Nigam Ltd (RVNL), a public sector enterprise, has emerged as the lowest bidder for a ₹145.35 crore Southern Railway project to design, supply, and commission traction substations on the Jolarpettai–Salem section. The project, part of Mission 3000MT, is scheduled to be completed in 540 days.
Alkem Laboratories, a leading pharmaceutical company, has launched Pertuza, a new indigenously developed breast cancer drug in India, to expand access to HER2-positive treatment.
Suraj Estate Developers, a real estate firm, launched Suraj Park View 1, a ₹250 crore value-luxury residential project at Shivaji Park, Dadar (West), Mumbai, with a saleable carpet area of 0.53 lakh sq. ft., under a capital-efficient redevelopment model.
Frequently Asked Questions
What is KFin Technologies known for?
KFin Technologies is known for providing financial technology solutions and services. It recently saw a potential stake sale by General Atlantic, a private equity firm.
What significant project has Brigade Enterprises announced recently?
Brigade Enterprises has signed a joint development agreement for a ₹1,200 crore residential project in Banashankari, South Bengaluru, spanning 7.5 acres.
What new orders has KEC International secured?
KEC International has bagged ₹3,243 crore worth of new T&D orders, including its largest-ever EPC order, spanning 400 kV transmission lines in the UAE and the supply of towers, hardware, and poles in the Americas.
How have IT stocks been affected by recent H-1B visa rule changes?
IT stocks have seen a significant market value loss of nearly ₹1 lakh crore, led by TCS and Infosys, due to recent H-1B visa rule changes.
What new product has Alkem Laboratories launched?
Alkem Laboratories has launched Pertuza, a new indigenously developed breast cancer drug in India, to expand access to HER2-positive treatment.